{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT02340845: Phase 2 Interventional Unknown status Cancer
(2014)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
USAN:LYSOSTAPHIN [USAN]
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
NCT01195948: Phase 1/Phase 2 Interventional Completed Uveitis
(2010)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00198289: Phase 2 Interventional Completed Staphylococcus Aureus
(2005)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02833506: Phase 1 Interventional Withdrawn Recurrent Fallopian Tube Carcinoma
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03334500: Early Phase 1 Interventional Active, not recruiting Prostate Cancer
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
USAN:CERGUTUZUMAB [USAN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02221960: Phase 1 Interventional Completed Recurrent or Metastatic Solid Tumors
(2014)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04596150: Phase 2 Interventional Completed Neoplasms
(2020)
Source URL:
Class:
PROTEIN
